EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
European Patent Office deals blow to pharma companies in dismissing their attempts to reinstate patents covering diabetes and obesity treatments | Inhibrx antibody patent upheld as Gilead subsidiary appeal is rejected.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
21 November 2024 Firm appoints Craig Bleifer as a partner in its New York office | Bleifer brings more than three decades of experience, including senior roles at Novo Nordisk and Daiichi Sankyo.
15 October 2024 Danish pharma company asserts 10 patents for drug that improves blood sugar levels in Type 2 diabetes patients | Like Novo’s Ozempic, the disputed drug can be used off-label to achieve weight loss.